Larvol Delta - Wugen-Begins-FirstinHuman-Phase-1-Clinical-Trial-of-WUNK101-its-Lead-Allogeneic-Memory-Natural-Killer-NK-Cell-Therapy-for-Patients-with-Relapsed-or-Refractory-RR-Acute-Myeloid-Leukemia-AML

WU-NK-101 - Wugen

https://www.businesswire.com/news/home/20230815212174/en/Wugen-Begins-First-in-Human-Phase-1-Clinical-Trial-of-WU-NK-101-its-Lead-Allogeneic-Memory-Natural-Killer-NK-Cell-Therapy-for-Patients-with-Relapsed-or-Refractory-RR-Acute-Myeloid-Leukemia-AML

Aug 15, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next